The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations
Open accessAbstract
Antisense-mediated exon skipping aiming for reading frame restoration is currently a promising therapeutic application for Duchenne muscular dystrophy (DMD). This approach is mutation specific, but as the majority of DMD patients have deletions that cluster in hotspot regions, the skipping of a small number of exons is applicable to relatively large numbers of patients. To assess the actual applicability of the exon skipping approach, we here determined for deletions, duplications and point mutations reported in the Leiden DMD mutation database, which exon(s) should be skipped to restore the open reading frame. In theory, single and double exon skipping would be applicable to 79% of deletions, 91% of small mutations, and 73% of duplications, amounting to 83% of all DMD mutations. Exon 51 skipping, which is being tested in clinical trials, would be applicable to the largest group (13%) of all DMD patients. Further research is needed to determine the functionality of different in-frame dystrophins and a number of hurdles has to be overcome before this approach can be applied clinically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hoffman, E. P., Fischbeck, K. H., Brown, R. H., Johnson, M., Medori, R., Loire, J. D., Harris, J. B., Waterston, R., Brooke, M., Specht, L., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198805263182104 · Cited by 927
Local Dystrophin Restoration with Antisense Oligonucleotide PRO051
van Deutekom, J. C., Janson, A. A., Ginjaar, I. B., Frankhuizen, W. S., Aartsma-Rus, A., Bremmer-Bout, M., den Dunnen, J. T., Koop, K., van der Kooi, A. J., Goemans, N. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa073108 · Cited by 781
Self-citationAartsma‐Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. B., & Den Dunnen, J. T. (2006) · Muscle & Nerve · doi:10.1002/mus.20586 · Cited by 739
Self-citationRescue of Dystrophic Muscle Through U7 snRNA-Mediated Exon Skipping
Goyenvalle, A., Vulin, A., Fougerousse, F., Leturcq, F., Kaplan, J.-C., Garcia, L., & Danos, O. (2004) · Science · doi:10.1126/science.1104297 · Cited by 506
Alter, J., Lou, F., Rabinowitz, A., Yin, H., Rosenfeld, J., Wilton, S. D., Partridge, T. A., & Lu, Q. L. (2006) · Nature Medicine · doi:10.1038/nm1345 · Cited by 494
Beggs, A. H., Hoffman, E. P., Snyder, J. R., Arahata, K., Specht, L. A., Shapiro, F., Angelini, C. I., Sugita, H., & Kunkel, L. M. (1991) · PubMed · Cited by 466
Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells
van Deutekom, J. C. T. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.15.1547 · Cited by 293
Self-citationAntisense-mediated exon skipping: A versatile tool with therapeutic and research applications
Aartsma-Rus, A., & van Ommen, G.-J. B. (2007) · RNA · doi:10.1261/rna.653607 · Cited by 267
Self-citationTherapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients
Aartsma-Rus, A. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg100 · Cited by 253
Self-citationBenchaouir, R., Meregalli, M., Farini, A., D'Antona, G., Belicchi, M., Goyenvalle, A., Battistelli, M., Bresolin, N., Bottinelli, R., Garcia, L., et al. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.09.016 · Cited by 236
Advances in Duchenne muscular dystrophy gene therapy
van Deutekom, J. C. T., & van Ommen, G.-J. B. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1180 · Cited by 221
Self-citationBéroud, C., Tuffery-Giraud, S., Matsuo, M., Hamroun, D., Humbertclaude, V., Monnier, N., Moizard, M.-P., Voelckel, M.-A., Calemard, L. M., Boisseau, P., et al. (2007) · Human Mutation · doi:10.1002/humu.20428 · Cited by 207
Antisense-Induced Multiexon Skipping for Duchenne Muscular Dystrophy Makes More Sense
Aartsma-Rus, A., Janson, A. A. M., Kaman, W. E., Bremmer-Bout, M., van Ommen, G.-J. B., den Dunnen, J. T., & van Deutekom, J. C. T. (2004) · The American Journal of Human Genetics · doi:10.1086/381039 · Cited by 200
Self-citationMorpholino Oligomer–Mediated Exon Skipping Averts the Onset of Dystrophic Pathology in the mdx Mouse
Fletcher, S., Honeyman, K., Fall, A. M., Harding, P. L., Johnsen, R. D., Steinhaus, J. P., Moulton, H. M., Iversen, P. L., & Wilton, S. D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300245 · Cited by 158
Arechavala‐Gomeza, V., Graham, I. R., Popplewell, L. J., Adams, A. M., Aartsma-Rus, A. M., Kinali, M., Morgan, J. E., van Deutekom, J. C., Wilton, S. D., Dickson, G., et al. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.061 · Cited by 152
Self-citationFamilial X‐linked myalgia and cramps
Gospe, S. M., Lazaro, R. P., Lava, N. S., Grootscholten, P. M., Scott, M. O., & Fischbeck, K. H. (1989) · Neurology · doi:10.1212/wnl.39.10.1277 · Cited by 142
Body-wide gene therapy of Duchenne muscular dystrophy in the mdx mouse model
Denti, M. A., Rosa, A., D’Antona, G., Sthandier, O., Angelis, F. G. D., Nicoletti, C., Allocca, M., Pansarasa, O., Parente, V., Musarò, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508917103 · Cited by 142
Kesari, A., Pirra, L., Bremadesam, L., McIntyre, O., Gordon, E. S., Dubrovsky, A. L., Viswanathan, V., & Hoffman, E. P. (2008) · Human Mutation · doi:10.1002/humu.20722 · Cited by 107
DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy
Gurvich, O. L., Tuohy, T. M. F., Howard, M. T., Finkel, R. S., Medne, L., Anderson, C. B., Weiss, R. B., Wilton, S. D., & Flanigan, K. M. (2007) · Annals of Neurology · doi:10.1002/ana.21290 · Cited by 101
Aartsma-Rus, A. M., Kaman, W. E., Weij, R., den Dunnen, J. T., van Ommen, G. B., & van Deutekom, J. C. T. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.02.022 · Cited by 91
Self-citationThe therapeutic potential of antisense-mediated exon skipping.
van Ommen, G. B., van Deutekom, J., & Aartsma-Rus, A. M. (2008) · PubMed · Cited by 83
Self-citationTakeshima, Y., Wada, H., Yagi, M., et al. (2001) · Brain and Development · doi:10.1016/s0387-7604(01)00326-6 · Cited by 80
Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy
Aartsma-Rus, A. M., Janson, A. A. M., van Ommen, G. B., & van Deutekom, J. C. T. (2007) · BMC Medical Genetics · doi:10.1186/1471-2350-8-43 · Cited by 77
Self-citationInduced dystrophin exon skipping in human muscle explants
McClorey, G., Fall, A., Moulton, H. M., Iversen, P. L., Rasko, J. E. J., Ryan, M. M., Fletcher, S., & Wilton, S. D. (2006) · Neuromuscular Disorders · doi:10.1016/j.nmd.2006.05.017 · Cited by 66
Carsana, A., Frisso, G., Tremolaterra, M. R., Lanzillo, R., Vitale, D. F., Santoro, L., & Salvatore, F. (2005) · Annals of Human Genetics · doi:10.1046/j.1529-8817.2005.00160.x · Cited by 62
Skipping toward Personalized Molecular Medicine
Hoffman, E. P. (2007) · New England Journal of Medicine · doi:10.1056/nejme0707795 · Cited by 60
Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy
Yokota, T., Pistilli, E. E., Duddy, W. J., & Nagaraju, K. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.6.831 · Cited by 56
Angelini, C. I., Fanin, M., Pegoraro, E., Freda, M. P., Cadaldini, M., & Martinello, F. (1994) · Neuromuscular Disorders · doi:10.1016/0960-8966(94)90071-x · Cited by 54
Drug evaluation: PTC-124--a potential treatment of cystic fibrosis and Duchenne muscular dystrophy.
Hamed, S. A. (2006) · PubMed · Cited by 48
Induction of revertant fibres in the mdx mouse using antisense oligonucleotides
Fall, A., Johnsen, R. D., Honeyman, K., Iversen, P. L., Fletcher, S., & Wilton, S. D. (2006) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-4-3 · Cited by 38
A Japanese boy with myalgia and cramps has a novel in‐frame deletion of the dystrophin gene
ISHIGAKI, C., Patria, S. Y., Nishio, H., et al. (1996) · Neurology · doi:10.1212/wnl.46.5.1347 · Cited by 16
Cited by
In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy
Nelson, C. E., Hakim, C. H., Ousterout, D. G., Thakore, P. I., Moreb, E. A., Rivera, R. M. C., Madhavan, S., Pan, X., Ran, F. A., Yan, W. X., et al. (2016) · Science · doi:10.1126/science.aad5143 · Cited by 1,144
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Kole, R., Krainer, A. R., & Altman, S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3625 · Cited by 1,152
Eteplirsen for the treatment of Duchenne muscular dystrophy
Mendell, J. R., Rodino‐Klapac, L. R., Sahenk, Z., Roush, K., Bird, L., Lowes, L. P., Alfano, L., Gomez, A. M., Lewis, S., Kota, J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23982 · Cited by 817
The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations
Bladen, C. L., Salgado, D., Monges, S., Foncuberta, M. E., Kekou, K., Kosma, K., Dawkins, H., Lamont, L., Roy, A. J., Chamova, T., et al. (2015) · Human Mutation · doi:10.1002/humu.22758 · Cited by 729
Self-citationRNA splicing factors as oncoproteins and tumour suppressors
Dvinge, H., Kim, E., Abdel-Wahab, O., & Bradley, R. K. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.51 · Cited by 687
Metadata
- Authors
- Aartsma-Rus, A., Fokkema, I., Verschuuren, J., Ginjaar, I., van Deutekom, J., van Ommen, G.-J., & den Dunnen, J. T.
- Venue
- Human Mutation
- Publisher
- Hindawi Limited
- Published
- 2009-03
- Volume
- 30
- Issue
- 3
- Pages
- 293-299
- ISSN
- 1059-7794 (ISSN-L)
- 1098-1004
- OpenAlex
- W2018862827
- Cited by
- 575
- References
- 31
- FWCI
- 14.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.